Core Viewpoint - The company, 拨康视云-B, has seen a significant increase in its stock price, with a rise of over 80% in the past week, following the successful patent applications for its core product CBT-009 in Japan and Europe [1] Group 1: Stock Performance - The stock price of 拨康视云-B increased by over 4% during intraday trading and is currently up by 2.71%, priced at 8.72 HKD, with a trading volume of 6.75 million HKD [1] Group 2: Patent and Product Development - The company announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully applied for patents in Japan and Europe for CBT-009, which is one of its core products [1] - The successful patent application is considered a significant milestone in the development process of CBT-009, enhancing its global coverage and facilitating commercialization [1] Group 3: Future Collaborations - The company anticipates that the patent success will enable collaborations with major pharmaceutical companies for the production, development, and distribution of CBT-009 in key high-end markets like Japan and Europe [1] - These collaborations and licensing arrangements are expected to enhance and accelerate the global commercialization potential of CBT-009 [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Bolekang Shiyun-B (02592), which rose over 4% during trading and has accumulated a gain of over 80% in the past week [1] - As of the report, the stock price is at 8.72 HKD with a trading volume of 6.7514 million HKD [1] - The company announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully applied for patents in Japan and Europe for its core product CBT-009, marking an important milestone in its development process [1] Group 2 - The successful patent applications are expected to enhance the global coverage of CBT-009 and facilitate its commercialization [1] - The company anticipates establishing licensing arrangements with major pharmaceutical companies for the production, development, and distribution of CBT-009 in Japan and Europe, which are key high-end markets [1] - These collaborations and licensing agreements are expected to boost and accelerate the global commercialization potential of CBT-009 [1]